The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...
BD will pay a $175 million civil penalty to settle charges from the Securities and Exchange Commission that the company misled investors about problems with its Alaris infusion pumps. The SEC issued a ...
FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...
BD has expanded a Class I Alaris recall to cover 15 additional pump infusion sets, the company said Friday. The Food and Drug Administration posted the company's notice on Monday. The company added ...